INTRODUCTION AND OBJECTIVES: It has been recently proven that robotic cystectomy was non-inferior to open cystectomy for 2-year progression-free survival.
It seems clear that robotic cystectomy offers lower rates of blood loss and transfusions compared to open cystectomy. However, it has yet to be determined if Intracorporeal Urinary Diversion, compared with Extracorporeal Urinary Diversion, has a lower risk of complications. We sustain that robotic cystectomy can offer better outcomes in nerve sparing. Therefore, in this video we present the technique we have used and the results we have obtained.
METHODS: We initiate the intervention performing the liberation of the seminal vesicles with Montsouris technique. We then make and incision in the peritoneum and dissect the vas deferens and seminal vesicles. After pulling the vas deferens, the Denonvilliers fascia is exposed. It can be safely open, so that we are able to create a posterior, intrafascial dissection plane to reach the apex of the prostate. When the ureter and the lateral pedicles of the urinary bladder are sectioned, and the endopelvic fascia is open, we perform a dissection of the intrafascial lateral plane of the prostate. Thus, we are able to safely clamp the vascular pedicles of the prostate and put together the two intrafascial planes, which are carefully widened to reach the uretra. We liberate the urethra so that we are able to separate it from the bundles. The urethra is clamped to avoid the dissemination of the tumoral cells, and then sectioned. RESULTS: We operated 51 patients with a mean age of 58.3; of those 46 were males. An Extracorporeal Urinary Diversion was performed in 14 of them, while 37 had an Intracorporeal Urinary Diversion. The ASA score was 2 in 24 of the patients, and 3 in 27 of them. Neoadjuvant chemotherapy was administered in 27 patients. A nerve sparing cystectomy was performed in 31 of them. The mean operating time was 406 minutes. There was no need to reconvert any operation. The estimated blood loss was 775 mL and 35% of the patients required a transfusion. The average length of hospital stay was 11.8 days. The majority of the tumors had urothelial origin, and the pathological stage varied widely. We have removed an average of 16.2 adenopathies. 3 of the patients were classified as N1 stage, and other 3 as N2 stage. All resection margins were tumor-free. Mean progressionfree survival at 2 years from the operation was 71%. 91% of the 31 men undergoing nerve sparing were potent with or without phosphodiesterase type 5 inhibitors CONCLUSIONS: In our series, the preservation of neurovascular bundles through the technique described above offers great outcomes.
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V06-08 ROBOT-ASSISTED RADICAL CYSTECTOMY AND HYBRID NEOBLADDER RECONSTRUCTION WITH THE AID OF GELPOINT DEVICE: TECHNICAL NUANCES AND PRELIMINARY RESULTS
Graziano Vignolini, Arcangelo Sebastianelli, Alessandro Pili, Campi Riccardo*, Francesco Sessa, Isabella Greco, Nicola Mormile, Pietro Spatafora, Mauro Gacci, Sergio Serni, Firenze, Italy INTRODUCTION AND OBJECTIVES: Robot-assisted cystectomy (RARC) with intracorporeal ileal neobladder can be offered to selected patients with muscle-invasive or high-risk non-muscle invasive bladder cancer. However, it represents a challenging surgical procedure with high morbidity rates and long operative time.
As a high-volume robotic center with a longstanding experience in open reconstructive surgery, we started a robotic program for RARC and herein we describe our step-by-step technique and preliminary results of RARC with hybrid modified vescica ileale padovana (mVIP) neobladder reconstruction, aiming to reduce morbidity and operative time.
METHODS: Between March 2018 and July 2018 selected patients with clinical T2N0M0 bladder cancer underwent RARC with hybrid mVIP reconstruction at our institution. Patients followed the ERAS protocol.
All the procedures were performed by a single surgeon with extensive experience in robotic urologic surgery and open radical cystectomy and ileal neobladder reconstruction.
Surgical technique for RARC replicated the principles of Collins technique with specific technical modifications. We used GelPOINT hand-assisted device and early clamping and section of the urethra (with a 12ch catheter), in order to obtain a timely removal of the tumorbearing bladder and lymph nodes avoiding potential tumor seeding, and to perform an extracorporeal bowel anastomosis and neobladder posterior wall and neck reconstruction. RARC was performed with DaVinci Si/Xi platform in a 4 arms configuration using a 0 lens. After induction of general anesthesia, with patient lying in supine position a 5 cm midline supraumbilical incision was made for GelPOINT access device.
A step-by-step overview of the reconstructive surgical technique is shown in the video accompanying the abstract. RESULTS: Overall, 5 patients underwent RARC with hybrid mVIP during the study period (4 males, 1 female). Median follow-up was 5 months. Median console time was 625 min. Median hospital stay was 11 days. Postoperative surgical complications occurred in 3/5 patients, including: 1 leakage from the urethro-neobladder anastomosis which required a prolonged catheterization time (31 days) and 2 early Clavien-Dindo Grade I, leading to the outage of ERAS protocol. No Clavien-Dindo > II or bowel complications were recorded and no cancer recurrences were observed. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e675
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